AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

EPCORE DLBCL-2, described as the first Phase 3 study of a bispecific antibody combination therapy in this setting, showed statistically significant and clinically meaningful improvement in progression-free survival for patients with newly diagnosed DLBCL. The provided article text gives no effect size, safety results, or further study details.